RxDoctor Payments Data

Eliana Ochoa, MD

Infectious Disease · McAllen, TXNPI 1114057304

Payments from drug & device makers

$641in general payments, 2019–2025

Across 9 payments — averaging $71.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$231
  • Merck$125
  • Melinta Therapeutics, LLC$124
  • AbbVie$93
  • Astellas Pharma US Inc$30
  • Takeda Pharmaceuticals U.S.A., Inc.$22
  • plus $17 from 1 others

What the payments were for

  • Food & beverage$61195%
  • Education$305%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$641 in reported general payments places this provider in the 50th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$120,423
Medicare patients
315
Services billed
1,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi31$113,680
DovatoDolutegravir Sodium/Lamivudine23$64,025
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf13$60,212
ErtapenemErtapenem Sodium138$55,886
JulucaDolutegravir/Rilpivirine14$47,421
Fosfomycin Tromethamine102$39,081
Daptomycin29$9,368
Meropenem51$6,572
Linezolid43$6,209
Itraconazole17$5,623
Voriconazole13$4,291
Epinephrine11$3,643
Cefepime Hcl21$3,365
CeftriaxoneCeftriaxone Sodium68$3,317
Vancomycin Hcl50$3,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Dovato, Juluca$17$225,12568 claims
Janssen Products, LPSymtuza$231$60,21213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 576 infectious disease providers in Texas.

Other infectious disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →